Daphne Karydas Biography and Net Worth

Director of Mineralys Therapeutics

Ms. Karydas currently serves as President and Chief Financial Officer of Flare Therapeutics Inc. where she has been since October 2021. Prior to Flare Therapeutics, she served as the Chief Financial Officer of Syndax Pharmaceuticals Inc. (Nasdaq: SNDX) from July 2020 to October 2021. From April 2017 to May 2020, Ms. Karydas held several roles at Allergan plc, including Senior Vice President of Corporate Strategy and Financial Planning & Analysis. Prior to her senior executive and top manager roles at these biotech and pharmaceutical companies, Ms. Karydas spent more than 15 years in investment banking and asset management roles that focused exclusively on the healthcare space, including biopharmaceuticals, life sciences and medical technologies. Ms. Karydas has previously served on the boards of directors at Elicio Therapeutics, LogicBio Therapeutics, Inc., and Eucrates Biomedical Acquisition Corp. (Nasdaq: EUCR). Ms. Karydas received a B.A. and M.S. in chemical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.

What is Daphne Karydas' net worth?: The estimated net worth of Daphne Karydas is at least $189.60 thousand as of March 31st, 2026. Karydas owns 6,200 shares of Mineralys Therapeutics stock worth more than $189,596 as of April 19th. This net worth estimate does not reflect any other investments that Karydas may own. Learn More about Daphne Karydas' net worth.
How do I contact Daphne Karydas?: The corporate mailing address for Karydas and other Mineralys Therapeutics executives is , , . Mineralys Therapeutics can also be reached via phone at 888-378-6240 and via email at [email protected]. Learn More on Daphne Karydas' contact information.
Has Daphne Karydas been buying or selling shares of Mineralys Therapeutics?: Daphne Karydas has not been actively trading shares of Mineralys Therapeutics within the last three months. Most recently, Daphne Karydas sold 3,000 shares of the business's stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $25.00, for a transaction totalling $75,000.00. Following the completion of the sale, the director now directly owns 6,200 shares of the company's stock, valued at $155,000. Learn More on Daphne Karydas' trading history.
Who are Mineralys Therapeutics' active insiders?: Mineralys Therapeutics' insider roster includes Srinivas Akkaraju (Director), Jon Congleton (CEO), Alexander Gold (Director), Daphne Karydas (Director), Adam Levy (Chief Financial Officer), David Rodman (Chief Medical Officer), and Brian Slingsby (Director). Learn More on Mineralys Therapeutics' active insiders.
Are insiders buying or selling shares of Mineralys Therapeutics?: In the last twelve months, Mineralys Therapeutics insiders bought shares 3 times. They purchased a total of 2,075,405 shares worth more than $52,354,246.50. In the last twelve months, insiders at the sold shares 41 times. They sold a total of 2,030,841 shares worth more than $79,343,423.50. The most recent insider tranaction occured on April, 15th when insider David Malcom Rodman sold 6,348 shares worth more than $175,585.68. Insiders at Mineralys Therapeutics own 25.6% of the company. Learn More about insider trades at Mineralys Therapeutics.
Information on this page was last updated on 4/15/2026.

Daphne Karydas Insider Trading History at Mineralys Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/31/2026	Sell	3,000	$25.00	$75,000.00	6,200
11/13/2025	Sell	15,000	$45.99	$689,850.00

Daphne Karydas Buying and Selling Activity at Mineralys Therapeutics

Mineralys Therapeutics Company Overview

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Today's Range

Now: $30.58

$30.05

$31.33

50 Day Range

MA: $27.32

$22.88

$31.74

2 Week Range

Now: $30.58

$12.59

$47.65

Volume

1,040,439 shs

Average Volume

1,348,451 shs

Market Capitalization

$2.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69